A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRATM) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer.

Project: Research

Project Details

Project Description

Effective start/end date27/04/2126/04/26


  • clinical trial
  • phase 1 and 2 study
  • treatment efficacy
  • treatment safety
  • Metastatic Cancer